Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bristol-Myers Squibb

59.66
-0.1600-0.27%
Volume:2.71M
Turnover:162.01M
Market Cap:121.07B
PE:-13.51
High:60.70
Open:59.91
Low:59.42
Close:59.82
Loading ...

Bristol Myers announces new five-year results from POETYK PSO trial

TipRanks
·
18 Feb

Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $54 From $52, Maintains Neutral Rating

MT Newswires Live
·
18 Feb

Bristol-Myers Squibb: Buy Rating Maintained Despite Opdualag Trial Setback, Strong Pipeline Expected to Drive Future Growth

TIPRANKS
·
17 Feb

Why Bristol-Myers Squibb (BMY) Is Among the Best Drug Stocks to Buy Now

Insider Monkey
·
17 Feb

Bristol Myers reports no new safety signals observed in five-year Sotyktu data

TIPRANKS
·
17 Feb

BRIEF-Bristol-Myers Squibb Co Says New Five-Year Sotyktu (Deucravacitinib) Data Show Consistent Safety And Durable Response Rates In Moderate-To-Severe Plaque Psoriasis

Reuters
·
16 Feb

Bristol-Myers Squibb Co - New Five-Year Sotyktu (Deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis

THOMSON REUTERS
·
16 Feb

Compugen Updates Filing Structure with Bristol Myers Squibb

TIPRANKS
·
16 Feb

Bristol Myers Squibb Co. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
15 Feb

BioArctic AB (BRCTF) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Profitability ...

GuruFocus.com
·
14 Feb

Bristol Myers Squibb Cancer Treatment Misses Primary Endpoint in Trial

Dow Jones
·
14 Feb

Bristol-Myers Squibb's Melanoma Treatment Fails to Meet Primary Endpoint in Phase 3 Adjuvant Trial

MT Newswires Live
·
14 Feb

BRIEF-Bristol Myers Squibb Provides Update On Phase 3 Relativity-098 Trial

Reuters
·
14 Feb

Bristol Myers’ Phase 3 RELATIVITY-098 for Opdualag did not meet primary endpoint

TIPRANKS
·
14 Feb

Bristol-Myers Squibb Co - Bms Phase 3 Relativity-098 Trial Fails to Meet Primary Endpoint

THOMSON REUTERS
·
14 Feb

Bristol-Myers Squibb Co - Opdulag Safety Profile Consistent With Known Profiles

THOMSON REUTERS
·
14 Feb